Estradiol Patch Shortage Tracker: What’s Backordered in 2026

It depends on which source you ask — and all of them are telling the truth.As of our July 1, 2026 review, the FDA had not listed the estradiol patch as in shortage; ASHP’s bulletin listed 14 patch products on back order or allocation; and Truveta’s real-world data showed patch use still rising, not falling. The honest one-line answer: the estradiol patch is not on the FDA’s shortage list, but it is on ASHP’s, and specific brands and strengths are hard to fill.

Two quick definitions, because they matter here. A “back order” means a manufacturer can’t currently ship a product. “Allocation” means a manufacturer is rationing a product to existing contracted customers. Neither shows up on the FDA’s list unless national supply crosses the agency’s threshold — and it hasn’t. Here is the reconciled snapshot.

Three sources, three vantage points, one reconciled picture: supply is genuinely tight for specific twice-weekly patch products, even though the FDA’s public shortage list has not flipped to “shortage.” The FDA weighs national supply reported by manufacturers; ASHP catalogs product-level problems; Truveta measures what actually left the pharmacy counter. They can all be right at once — and reporting from The New York Times(February 2026) and NPR (March 2026) has documented patients struggling to fill specific brands and strengths even as the FDA’s list stayed clear.

What this does notshow is your local pharmacy’s shelf. A product we list as “available” may be out of stock at your store this week, and a product on the affected list may be sitting behind the counter across town. This is a national source tracker, not a live inventory checker — and it is educational information, not medical advice. If your patch is unavailable, your pharmacist and prescriber are the right people to sort out a substitute.

We assembled this from primary sources and did the counting ourselves.We read the FDA’s public shortage database and the agency’s on-the-record statements, pulled ASHP’s “Estradiol Transdermal System” bulletin directly, and counted every product it lists as affected and as available. For demand, we used Truveta’s published real-world analysis rather than secondhand summaries.

Our counting rule is simple and reproducible: each package-level code (National Drug Code, or NDC) that ASHP lists counts once. Codes under “Products Affected” count as affected; codes under “Available Products” count as available. We do not treat forum posts, pharmacy anecdotes, or clinic marketing pages as shortage evidence — those describe how people experience the problem, not what’s true. Every figure below carries a source and a date. For a plain-language guide to the terminology used here, see our Menopause & HRT Glossary.

• FDA position:confirmed through the FDA’s public statements (including from FDA Commissioner Marty Makary) and reporting, plus Truveta’s note that no FDA shortage announcement had been made during its study period. Check the live FDA Drug Shortages database for the current status.
• ASHP product status: ASHP Drug Shortage Bulletin, "Estradiol Transdermal System" (id=1206), updated April 22, 2026. We confirmed the live bulletin on July 1, 2026.
• Demand data: Truveta Research, published April 9, 2026, reflecting data as of March 30, 2026.

As of the April 22, 2026 ASHP bulletin, 14 estradiol-patch products were affected, and every single one was a twice-weekly patch.They come from three manufacturers — Amneal (across both its Dotti and Lyllana brands), Noven, and Zydus — spread over four brand groupings. No once-weekly patch appears anywhere on the affected list, a pattern that points straight at where the squeeze is.

Twice-weekly patches (applied two times a week, sold in 8-count boxes) include Dotti, Lyllana, Vivelle-Dot, and Minivelle. Once-weekly patches (applied once a week, sold in 4-count boxes) include Climara. Some manufacturers make both. The affected products sit entirely on the twice-weekly side.

For anyone who needs product-level specificity — a pharmacist confirming a substitution, or a writer who wants the exact codes — here are the 14 affected products with their NDCs. We compiled these from the ASHP bulletin and confirmed them against the live page on July 1, 2026.

The concentration is the story. Sort the same bulletin by dosing schedule and the pattern is stark: every affected product is a twice-weekly (8-count) patch, while every once-weekly (4-count) product is listed available.

ASHP’s bulletin lists 32 estradiol-patch products as available — more than twice the number affected — including every once-weekly option. Availability leans heavily toward once-weekly (4-count) patches from Bayer, Viatris/Mylan, and Sandoz, which each list the full strength range. National availability is not a promise your pharmacy has stock, but it does mean the bulletin is far from describing every estradiol patch as unavailable. Here is the complete available list from the April 22, 2026 bulletin.

One detail ASHP flags directly: Bayer had short-dated Climara 0.06 mg/24h once-weekly patches available with an expiration date of March 2027. “Short-dated” means the stock is real but closer to its expiration date than usual — check the date printed on the package and ask your pharmacist if you have questions.

The two lists diverge because they are built from different inputs and answer different questions — not because one is wrong.The FDA’s determination leans on data manufacturers report about national supply, and the agency’s shortage program generally does not chase shortages it expects to resolve quickly, shortages limited to a single strength or package size, or situations where substitute strengths and package sizes are available. ASHP’s bulletins are prompted by frontline reports from clinicians and pharmacists, which surfaces the twice-weekly squeeze fast.

There’s a measurement trap underneath all of it. When patches get hard to find, prescribers quietly switch patients to gels, sprays, or oral estradiol — so the “unmet demand” for patches never fully registers in a national supply model. That’s a big reason a real, lived shortage of specific products can coexist with an FDA “not in shortage” status. Being absent from the FDA’s list is not the same as being easy to fill everywhere; it mostly means one national threshold hasn’t been crossed.

The demand signal is unambiguous, and it comes from real-world dispensing data, not a survey.Truveta reported that estrogen patch dispensing more than tripled — from 6.2 to 19.9 per 1,000 women between 2018 and February 2026 — making the patch the single most common form of estrogen therapy by early 2026. Prescribing among women aged 45–54 rose 184.2% over the same window, reaching roughly 1 in 20 women in that group.

Supply, meanwhile, is structurally slow to respond. Only about six manufacturers make estradiol patches for the U.S. market, and transdermal patches are, in Sandoz’s own words to CNBC, “highly complex” to manufacture. ASHP’s Michael Ganio has explained that generic makers often run a product on a shared production line for part of the year and then switch that line to something else — so adding output can mean waiting for the next cycle, a harder call for generics because they carry lower margins than brand-name drugs.

But we won’t let the demand story quietly become a causation claim. The bulletin is careful about whyeach product is short, and so are we. Here is exactly what the sources establish — and where the explanation runs out.

There’s also an honest wrinkle we won’t paper over: Truveta explicitly reported that it did notsee patch dispensing decline despite the shortage reports, and that no FDA shortage announcement had been made during its study period. The likely explanation is timing — patches are often dispensed in 30- or 90-day supplies, and patients switch brands or pharmacies to get filled — so a real disruption can take months to show up in dispensing data.

There is no single national end date, and the resupply picture varies sharply by manufacturer.ASHP’s bulletin gives no release estimate for the affected Amneal products, describes Noven’s supply as intermittent with weekly releases, and describes Zydus as rationing to existing customers — three different situations under one “shortage” headline. Here is what each affected manufacturer reported.

The direction has been worsening, not easing. AARP reported ASHP listed 10 estrogen-patch products as of February 2026; the bulletin we counted in April lists 14 affected products. Beyond the manufacturers’ own statements, the broader timeline isn’t knowable from the public bulletin — ASHP assigns no end date. The FDA has said it is monitoring supply and assisting manufacturers, but the agency’s list still shows no shortage. We’ll update this section as the manufacturer notes change.

This shortage is a supply-side hangover from a genuine shift in how menopause is treated.For two decades, hormone-therapy use sat well below its earlier peak after a 2002 Women’s Health Initiative study prompted strong safety warnings. In late 2025 the labeling changed, and demand responded fast. Here is the dated sequence.

We’re placing this context after the data on purpose, and framing it carefully: demand rose sharply, a small group of manufacturers couldn’t add complex patch capacity fast enough, and the strain landed hardest on twice-weekly products. Whether the labeling change causedany specific product shortage is a broader claim than any single source establishes — which is why the cause ledger above sticks to what’s provable.

We’d rather tell you where this data stops than let you over-read it. A few honest limits:

• National status is not local inventory. A product listed as available may be out of stock at your pharmacy today, and vice versa. We do not track individual pharmacy shelves.
• Sources lag reality.ASHP updates as reports come in; the FDA’s data depends on manufacturer reporting; Truveta’s dispensing data can trail real supply changes by weeks because of 30- and 90-day fills. A snapshot is a snapshot, which is why we date everything.
• “Not on the FDA list” is not “no problem.” The two systems use different thresholds and different public formats.
• We don’t tell you what to take.This page reports supply status. It does not recommend switching products, and it is not a substitute for your prescriber or pharmacist, who can advise on FDA-approved alternatives — estradiol also comes as gels, sprays, oral tablets, and vaginal forms (see our FDA-Approved HRT Reference for a full category breakdown) — as well as dose equivalence and whether a brief gap is acceptable. Compounded estradiol is a separate category that is not FDA-approved, and quality can vary; that’s a conversation for a clinician, not a default.